BioCorRx Inc. · OTC:BICX
BioCorRx — Investor Presentation (September 2015)
17 slides from BioCorRx's investor presentation, Sep 22, 2015
Slide 1: BioCorRx, Inc. (Ticker: BICX) Investor Presentation
Slide 2: Safe Harbor Statement
=a Safe Harbor Statement The information in this investor presentation may include forward-lookin statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan,” "will," and similar expressions. These forward-looking statements i
Slide 3: BioCorRx, Inc. Investor Snapshot
BioCorRx, Inc. Investor Snapshot Ticker: Price: Market Cap. Revenue (ttm): Qtrly. Revenue Growth: Insider Ownership: Long-term Debt: BICX $0.049 $7.68 million $1.54 million 92% 34% $1.3 million BioCorRx, Inc. seeks to brand and expand addiction treatment by licensing its comprehensive and affordable
Slide 4: The Addiction Treatment Sector
=e The Addiction Treatment Sector © Insurance Mandates Expand Addiction Treatment Coverage Substance abuse now included in 10 core health care mandated benefits * Increased treatment availability to Medicaid and individual/small group markets © Large, Fragmented Market © No dominant player and no na
Slide 5: The Addiction Problem
The Addiction Problem Alcohol ‘$30 Billion $235 Billion Mlicit Drugs su Billion $193 Billion * 23.5 million Americans are addicted to drugs and alcohol* * 17 million adults in the U.S. are alcohol-dependent 85% of people with alcohol abuse or dependence go untreated Over 2 million people in the U.S.
Slide 6: The Treatment Problem
The Treatment Problem ‘Addiction not treated as ‘chronic disease - Research shows combining 5 High relapse rate {treatment medications with pia eons behavior therapy is the best ‘way to ensure success for most £8196 patient dropout rate in Poor patient poe first 30 days for behavior only ‘compliance
Slide 7: BioCorRx Recovery Program
= Propri BioCorRx® Recovery Program A Medication-assisted Treatment (MAT) program for treating alcohol and opioid addiction that combines a Naltrexone Implant with structured counseling. * Naltrexone Implant * Opioid receptor antagonist that works in the brain’s reward system, blocks the pleasant ef
Slide 8: BioCorRx Recovery Program
BioCorRx® Recovery Program * Treated several hundred patients since 2010 © Unprecedented Success Rates* * Currently 11 treatment facilities in the U.S using the BioCorRx® Recovery Program * Exclusive U.S and International distribution rights for the program** * Distribution agreement in place with p
Slide 9: BioCorRx vs. Other Treatment Solutions
= —$— $$ ene BioCOrRx vs vs. Other Programs her Treatment Solutions Poor treatment outcomes Limited drug effectiveness Traditional Residential Rehab can be expensive Decreased compliance Lack of privacy Major interruption to life BioCorRx Recove Program Unprecedented success rate Lasts several month
Slide 10: Established Distribution
Established Distribution \ > Established business model > National and local recruitment and media plans > Documented counseling procedures > Scalable business SOPs > Repeatable business and training practices and processes
Slide 11: Strategic Partnerships
Strategic Partnerships * Trinity Compound Solutions * Licensees * Outpatient Addiction Clinics * Myriad Medical Marketing* + Physical Medicine Center Network*
Slide 12: Financial Highlights
_=—— li Financial Highlights
Slide 13: Quarterly Revenue Growth Goals
_= ——- Quarterly Revenue Growth Goals 8 Coe ———- mm vl i ee oF aeae @ & QIAN — a @ O O% ee aw G*:Goal 2013 2014 2016 [G] 2017 [G] Revenue in Millions ($) 3 ou oe 8 we ft
Slide 14: BioCorRx Annual Revenue Growth Goals
BioCorRx Annual Revenue Growth Goals Revenue in Millions (8) Gh Goal — = in)
Slide 15: BioCorRx Quarterly EBITDA Growth Goals
_ BioCorRx Quarterly EBITDA Growth Goals _aal ll EBITDA in Millions (3) ‘ aaa Bea & @ QIGIQIG) VBUaea B&O G*: Goal 2013 2014 2015 2016 [G] 2017 [G]
Slide 16: BioCorRx Annual EBITDA Growth Goals
_ BioCorRx Annual EBITDA Growth Goals ions (5) EBITDA in Mil 2014 2015 [G] 2016 [G] 2017 [G] G*: Goal 20:
Slide 17: Investment Summary
Investment Summary Unique, proven business model with largely fragmented competition > Opportunity to be a disruptor in a $35 billion dollar market Grew program sales over 400% in 2014 Took company from one location to 11 in just over a year Became cash flow positive in 2014 Eliminated convertible d